Skip to main content
. 2016 Mar 14;6:22996. doi: 10.1038/srep22996

Figure 1. RNLS overexpression in cancer, and association with poor patient outcome in PDAC.

Figure 1

(A) RNLS mRNA level measured by qPCR in cDNA arrays containing 182 human tumor samples (OriGene Technologies) from 15 different tumor types; *indicates p < 0.05, **indicates p = 0.0001. (B) RNLS mRNA level measured by qPCR in normal pancreas (n = 6), pancreatic ductal adenocarcinomas (n = 11), and pancreatic neuroendocrine tumors (n = 23); *indicates p = 0.05; **indicates p = 0.00017. (C) RNLS protein expression detected by immunohistochemistry using m28-RNLS in normal human pancreatic tissue (left panel, n = 90), ductal adenocarcinoma (Grades 1–4, n = 20 each); representative result shown for each; RNLS protein stains brown. (D) RNLS expression detected using anti-RNLS-m28 for immunofluorescence staining of tissue microarray of normal human pancreatic tissue (left panel, n = 90), ductal carcinoma (middle panel, n = 90); representative result shown for each, and blue color: nuclei, green color: cytokeratin, and red color: RNLS; right panel: fluorescence intensity quantified using the AQUAnalysisTM software, normal human pancreatic tissue (n = 90), ductal carcinoma (n = 90), ***indicates p = 0.00013. (E) Kaplan-Meier survival curve for survival rates; Biomax cohort of 69 PDACs stratified into low (n = 35, RNLS AQUA score < median) and high (n = 34, RNLS AQUA score > median) RNLS expression, *indicates p = 0.0001.